Hulio, Humira Biosimilar, Gets FDA Nod for Crohn’s, UC, But Not Available Until 2023
News
The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), for the treatment of adults with Crohn’s disease and ulcerative colitis — both forms of inflammatory bowel disease. ... Read more